The Study
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
This isn't a study that tests liraglutide in people — it's more like a commentary or opinion about what the FDA found. It can tell us what might be good or bad about the drug, but it doesn't prove anything on its own.
Analysis score
Maximum 0 for a editorial/opinion.
Where the score came from
Doctors are looking at a new medicine for diabetes called liraglutide. It can help, but might also have big side effects.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes, this matters because doctors need to decide if the help from the medicine is worth the possible harm.
- 2The medicine helps with diabetes but could have serious risks.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The New England journal of medicine
Year
2010
Authors
Mary H. Parks, C. Rosebraugh
Related Content
Claims (2)
The FDA looked at both the good things and the possible risks of a new diabetes drug called liraglutide to decide if it's safe and helpful for patients.
Liraglutide can help treat diabetes, but it might also have serious side effects — so doctors need to think carefully about each person’s health before prescribing it.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.